Chenchen Liu

The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies. More than 80% of patients are diagnosed at an advanced stage, and the 5‑year survival rate remains approximately 13% [ 1 , 2 ]. For patients with metastatic PDAC (mPDAC), first-line chemotherapy...